Loading…
Loading…
just wondering why you couldn't attack immunology broadly in the same way as you have obesity, investing earlier, faster, and more aggressively
how the competitors' dynamics are playing out and how you, Dave and Dan see the market evolving from here
hoping, Dave, you could discuss a little bit more your views on the path for price with orforglipron and the growing number of assets coming to market
How is Ebglyss tracking against your ambition of it being a best in class launch? Is your vision for peak sales in line with consensus sales of $2 billion